Global Preeclampsia Diagnostics Market is expected to witness a single-digit growth rate by 2027
Growing number of lifestyle conditions, the need for more advanced diagnostic tests, the rise in preterm birth rates, and increased research and development efforts into preeclampsia biomarkers are all contributing to the preeclampsia diagnostics market expansion.
Preeclampsia is a dangerous pregnancy-related condition that may be extremely dangerous for both moms and babies globally. It is characterized by elevated blood pressure and an excess of protein in the urine. It is a prevalent hypertension problem during pregnancy in both industrialized and developing nations, and it commonly results in premature and underweight newborns. If preeclampsia is not identified and treated early, it may result in eclampsia, preterm birth, organ failure, seizures, and potentially fatal consequences for the mother and child.
Global Preeclampsia Diagnostics Market Dynamics
Preeclampsia is a pregnancy-related illness characterized by elevated blood pressure and signs of organ damage, most frequently to the kidneys and liver. The heightened incidence of preeclampsia worldwide has served as a major catalyst for the creation of novel diagnostic and therapeutic approaches. Prompt intervention and therapy are now possible due to improved and earlier detection of preeclampsia brought about by ongoing developments in diagnostic technologies. For instance,
- In November 2022, Biora Therapeutics, Inc.disclosed the successful completion of a licensing agreement with Avero Diagnostics (formerly Northwest Pathology) for the commercial development of its Preecludia™ rule-out test for preeclampsia
Research and development (R&D) activities by pharmaceutical companies and academic institutions are aimed at developing more effective and minimally invasive preeclampsia therapies, which might propel future market expansion. The market is expanding as a result of government initiatives, greater consumer awareness, funding for research investigations, and other factors. Working together, pharmaceutical companies, academic institutions, and healthcare organizations can advance research and develop novel therapies for preeclampsia. The market benefits from initiatives to inform patients and medical professionals about the risks and early warning indicators of preeclampsia, which aid in early diagnosis and treatment.
Preeclampsia Diagnostics Market : Predictive biomarkers, diagnosis, and risk factors
Worldwide, the prevalence of preeclampsia, a frequent pregnancy complication, is rising. Because of the increased blood pressure that occurs during pregnancy as a result of lifestyle changes, poor food, sedentary behavior, alcohol intake, and mental stress, there is an increased requirement for preeclampsia diagnostic testing. Preeclampsia is becoming more common, and risk factors including diabetes, obesity, and advanced maternal age might help explain why.
The search for prognostic biomarkers for preeclampsia has gained more attention recently. Timely delivery, focused observation, and early diagnosis are all made easier with a trustworthy predictive test. Clinical importance exists for a biomarker that can detect high-risk pregnant women and prevent preterm preeclampsia. For instance,
- In June 2023, Diabetomicspresented the results of clinical studies on first-trimester screening and diagnostic support for preeclampsia at the 20th World Congress in Fetal Medicine in Valencia, Spain. The result stated that the addition of GlyFn as a supplementary biomarker to the FMF ‘Triple’ screening test for preterm preeclampsia has notably improved the screening performance, but further validation in diverse populations is necessary to confirm these findings
- In May 2023, Thermo Fisher’sreceived FDA approval for its immunoassays designed for the evaluation of preeclampsia risk. These are the first immunoassays to receive breakthrough designation and FDA clearance, which will assess the risk of developing preeclampsia and support clinical management, marking a significant advancement in addressing this severe pregnancy complication
Key Challenges of the Preeclampsia Diagnostics Market
Preeclampsia’s complexity needs a multidisciplinary approach comprising maternal-fetal medicine specialists, obstetricians, and other healthcare providers. The integration of such services may meet roadblocks, impeding market expansion. The lack of awareness regarding preeclampsia in developing nations, as well as a lack of understanding among healthcare practitioners about effective screening techniques for the illness, is projected to stymie market growth in emerging countries.
North America Accounts for the Largest Share of the Global Preeclampsia Diagnostics Market
The North American area dominates the global market for preeclampsia diagnostics, accounting for the lion’s share. This dominance is attributable to increased healthcare expenditures, broad acceptance of improved goods, and favorable government actions recognizing the seriousness of the issue. The rising frequency of preeclampsia is driving up medical treatment expenses for preeclampsia patients and their babies. The Asia-Pacific area is expected to develop at the fastest CAGR, owing to the region’s high pregnancy rate, increased illness awareness, and growing population.
Competitive Landscape Analysis of the Preeclampsia Diagnostics Market
The global preeclampsia diagnostics market is dominated by some of the key players which include Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG Instruments GMBH, Metabolomic Diagnostics Ltd., Bayer AG, Sera Prognostics, and Diabetomics, Inc. among others.
Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold in the Preeclampsia Diagnostics Market
Players operating in this market are adopting both organic and inorganic growth strategies such as receiving grants for research, entering into collaborations, and acquiring related firms to garner market share. For instance,
- In February 2023, Boston University’sWendy Kuohung, MD, received a grant of $99,994 USD from the Preeclampsia Foundation for new research aimed at investigating genetic targets with the potential to develop therapeutics/diagnostic solutions for preeclampsia.
- In May 2022, Sera Prognostics Inc., recognized as The Pregnancy Company®, in collaboration with the Newborn Foundation, unveiled the initiation of the Every Mother, Every Baby Project. This initiative aims to reduce maternal and neonatal mortality and morbidity by addressing risks linked to unexpected preterm birth.
Preeclampsia is expected to become more common, and firms are expected to drive the market with aggressive organic and inorganic development strategies, greater research and development for preeclampsia biomarkers, and a growing demand for improved diagnostic tests.
Get Detailed Insights on the Preeclampsia Diagnostics Market @ https://meditechinsights.com/preeclampsia-diagnostics-market/
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have successfully completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
